Literature DB >> 6349765

Bacille Calmette-Guérin as maintenance therapy for non-Hodgkin's lymphoma.

J W Thomas, I H Plenderleith, S Landi, V E Basco, D V Clements.   

Abstract

Following complete remission of non-Hodgkin's lymphoma by chemotherapy, irradiation or both, 44 patients were studied to assess the value of bacille Calmette-Guérin (BCG) as maintenance therapy. Patients with stage LI, EI or EII disease were allocated at random to receive BCG or no further maintenance therapy, and those with stage LII, LIII, EIII or IV disease received BCG therapy or orally administered cyclophosphamide. BCG had no effect on the duration of remission or the overall survival from the time of randomization. However, after the first recurrence there was a significant improvement in survival in the patients who had received BCG maintenance therapy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6349765      PMCID: PMC1875167     

Source DB:  PubMed          Journal:  Can Med Assoc J        ISSN: 0008-4409            Impact factor:   8.262


  5 in total

1.  Delay in progression of malignant lymphoma after BCG vaccination.

Authors:  J E Sokal; C W Aungst; M Snyderman
Journal:  N Engl J Med       Date:  1974-12-05       Impact factor: 91.245

Review 2.  Acute leukemia in adults.

Authors:  M E Beard; G H Fairley
Journal:  Semin Hematol       Date:  1974-01       Impact factor: 3.851

3.  Active immunotherapy for acute lymphoblastic leukaemia.

Authors:  G Mathé; J L Amiel; L Schwarzenberg; M Schneider; A Cattan; J R Schlumberger; M Hayat; F De Vassal
Journal:  Lancet       Date:  1969-04-05       Impact factor: 79.321

4.  Examining survival data.

Authors:  A J Coldman; J M Elwood
Journal:  Can Med Assoc J       Date:  1979-10-20       Impact factor: 8.262

5.  Improved complete remission rates and survival for patients with large cell lymphoma treated with chemoimmunotherapy. A Southwest Oncology Group Study.

Authors:  S E Jones; P N Grozea; E N Metz; A Haut; R L Stephens; F S Morrison; R Talley; J J Butler; G E Byrne; R Hartsock; D Dixon; S E Salmon
Journal:  Cancer       Date:  1983-03-15       Impact factor: 6.860

  5 in total
  1 in total

1.  Maintenance therapy with interferon alfa 2b in patients with diffuse large cell lymphoma.

Authors:  A Avilés; J C Díaz-Maqueo; E L García; A Talavera; R Guzmán
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.